Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 308Lung Neoplasms 70Neoplasms 50Neoplasm Metastasis 33Parkinson Disease 4, Autosomal Dominant Lewy Body 20Colorectal Neoplasms 20Carcinoma 20Mesothelioma 15Breast Neoplasms 15Mesothelioma, Malignant 13Small Cell Lung Carcinoma 11Melanoma 10Adenocarcinoma 10Neoplasms by Site 9Adenocarcinoma of Lung 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Lung Diseases 7Thoracic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Non-Squamous Non-Small Cell Lung Cancer 6Uterine Cervical Neoplasms 5Respiratory Tract Neoplasms 5Respiratory Tract Diseases 5Recurrence 5Rectal Neoplasms 5Neoplasms by Histologic Type 5NSCLC 5Head and Neck Neoplasms 5Endometrial Neoplasms 5

Interventions

Carboplatin 2tislelizumab 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-squamous Non-small-cell Lung Cancer × Pemetrexed × Clear all
NCT06416410 2025-04-04

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Allist Pharmaceuticals, Inc.

Phase 3 Recruiting
392 enrolled
Thoracic

Advanced Non-squamous Non-small-cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡